MedTrace Logo

Zinc Containing Vaginal Topical " Suppository "

NCT05453227 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2023-10-17

No results posted yet for this study

Summary

The genitourinary syndrome of menopause (GSM) is a new term that describes various menopausal symptoms and signs associated with physical changes of the vulva, vagina, and lower urinary tract.

The GSM includes not only genital symptoms (dryness, burning, and irritation) and sexual symptoms (lack of lubrication, discomfort or pain, and impaired function), but also urinary symptoms (urgency, dysuria, and recurrent urinary tract infections \[UTI\])

Conditions

  • Genitourinary Syndrome of Menopause

Interventions

DRUG

Zinc

To test the effect of a novel zinc-containing vaginal topical on GSM/VVA symptoms.

Sponsors & Collaborators

  • Egymedicalpedia

    lead INDUSTRY

Principal Investigators

  • Assem Anwar, Professor · Department of Obstetrics & Gynecology Faculty of Medicine for boys, Al-Azhar University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
55 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-01
Primary Completion
2022-12-01
Completion
2022-12-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05453227 on ClinicalTrials.gov